Allogene Therapeutics (ALLO) Cash from Operations (2018 - 2026)

Allogene Therapeutics has disclosed Cash from Operations across 9 years of filings, most recently posting 12913000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 12913000.0, up 75.6% year-over-year; the trailing twelve-month figure through Mar 2026 was 109230000.0 (up 44.65% YoY), and the FY2025 annual result was 149246000.0, up 25.49% from the prior year.
• Cash from Operations came in at 12913000.0 for Q1 2026 at Allogene Therapeutics, up from 27599000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 12913000.0 in Q1 2026 to a low of 68237000.0 in Q1 2022.
• The 5-year median for Cash from Operations is 52929000.0 (2025), against an average of 48277117.65.
• Across the five-year window, Cash from Operations plunged 45.44% in 2023 and soared 75.6% in 2026, its largest moves.
• Allogene Therapeutics' Cash from Operations stood at 62096000.0 in 2022, then rose by 13.51% to 53707000.0 in 2023, then jumped by 31.67% to 36698000.0 in 2024, then grew by 24.79% to 27599000.0 in 2025, then jumped by 53.21% to 12913000.0 in 2026.
• The last three Cash from Operations figures came in at 12913000.0 (Q1 2026), 27599000.0 (Q4 2025), and 29688000.0 (Q3 2025), per Business Quant data.